Catalent Pharma Solutions Appoints New Sterile Segment President, Sales and Marketing Head
SOMERSET, N.J., Sep 28, 2009 (BUSINESS WIRE) --
Companies: Innovex, Inc (INVX),
Catalent Pharma Solutions, Inc. announced today the appointment of Will Downie in a dual role as Group President, Sterile Technologies and Senior Vice President of Global Sales & Marketing, effective October 12, 2009. Mr. Downie will have full accountability for the Sterile Technologies segment, which includes the Company's injectable manufacturing businesses in Brussels, Belgium and Limoges, France, as well as its blow-fill-seal business, based in Woodstock, Illinois. In addition, Mr. Downie will lead the global sales and marketing functions, including Catalent's Global Account Sales team. Mr. Downie will report to John Chiminski, President and CEO of Catalent, and will be based in Catalent's Swindon, United Kingdom office.
Mr. Downie most recently served as Vice President and Global Leader of GE Healthcare's Molecular Imaging business, where he was responsible for leading a global organization of 1,800 people, with five manufacturing sites and revenues of approximately $650 million annually. His prior positions at GE Healthcare include VP and General Manager of Medical Diagnostics -- Europe, Middle East and Africa; Vice President and General Manager -- Europe; and Vice President of Sales for Medical Diagnostics -- Europe. Prior to GE Healthcare, Mr. Downie held senior management positions in operations, sales and marketing at Innovex UK Limited, a contract sales division of Quintiles. Mr. Downie also held prior commercial leadership positions with Sanofi-Synthelabo UK, Sanofi-Winthrop Limited, and Merck. Mr. Downie holds a Bachelor of Science degree in Biochemistry from the University of Edinburgh.
John Chiminski, Catalent's President and CEO, said, "I am pleased to welcome Will to the Catalent executive team. I've worked with him for a number of years, and I believe Will's unique combination of business management experience and sales and marketing expertise will help us accelerate organic growth for both our Sterile business and the Company overall."
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue. For more information, visit www.catalent.com.